ライフサイエンスコーパス: immunoadhesin

1 dent (NIH 3T3 and NRK) cells to an HTLV-1 SU immunoadhesin.

2 nst RCANBP virions and SU-A-immunoglobulin G immunoadhesin.

3 oduced between the D1 and Fc portions of the immunoadhesin.

4 studies were performed with a subgroup A SU-immunoadhesin.

5 ally reduced the binding affinity for the SU-immunoadhesin.

6 eductions in the binding affinity for the SU-immunoadhesin.

7 tant structural and functional principles of immunoadhesins.

8 Recent studies suggest that immunoadhesins also may be useful therapeutically, as in

9 ding of the HTLV-1 surface glycoprotein (SU) immunoadhesin and transduction by HTLV-1 pseudotyped vir

10 olyethylene glycol-conjugated Fab molecules, immunoadhesins, and albumin fusions, suggesting a novel

11 tion, we highlight some unique advantages of immunoadhesins as experimental tools in biology, as well

12 ivalent PECAM-1 in the form of a PECAM-1/IgG immunoadhesin, associated homophilically with cells expr

13 These immunoadhesins bind beta-glucan with high affinity, and

14 The SU-immunoadhesin bound the wild-type Tva protein with a KD

15 Furthermore, immunoadhesins can be used not only to impair but also t

16 f BDNF is critical to this effect we used an immunoadhesin chimera (TrkB-IgG) that inactivates free B

17 We used a specific immunoadhesin chimera (TrkB-IgG) that mimics the BDNF re

18 investigated the neutralization potencies of immunoadhesins compared to those of their parent IgGs.

19 between the TEF CAR1-related protein and an immunoadhesin composed of the surface (SU) envelope prot

20 ne-stimulating properties, we have developed immunoadhesins consisting of the carbohydrate binding do

21 Blockade of FasL with a soluble Fas immunoadhesin does not prevent liver injury in animals t

22 An immunoadhesin form of one of these, CCR5mim2-Ig, synergi

23 ed to those of the parent IgG, and the VRC01 immunoadhesin formed dimers and multimers with reduced n

24 ciently than CD4-Fc or equimolar mixtures of immunoadhesin forms of each peptide.

25 eraction of HAV with havcr-1, we constructed immunoadhesins fusing the hinge and Fc portion of human

26 geting, which is based on the application of immunoadhesins, genetically engineered fusion proteins t

27 ector expressing antibodies or antibody-like immunoadhesins having predetermined SIV specificity.

28 acting partners; for example, use of a novel immunoadhesin HN125 to interfere MUC16 binding to mesoth

29 enerated an HTLV-I surface glycoprotein (SU) immunoadhesin, HTSU-IgG, which binds specifically to cel

30 y near-quantitative formation of an antibody/immunoadhesin hybrid in a cotransfection assay.

31 Such proteins, known as immunoadhesins (IA), were highly expressed following tra

32 An immunoadhesin is a fusion protein that combines the targ

33 The prototypic immunoadhesin is an antibody-like molecule that fuses th

34 rahippocampal infusion of an EphA antagonist immunoadhesin leads to impaired performance in two behav

35 These immunoadhesins modulate the activity of not only a singl

36 glycosylation experiments using TNFR-IgG, an immunoadhesin molecule, as a model therapeutic glycoprot

37 CCR5- and CD4-mimetic peptides, expressed as immunoadhesins, neutralize HIV-1 more efficiently than C

38 extracellular domains of LFA-1 and a dimeric immunoadhesin of ICAM-1.

39 Immunoadhesins provide a unique tool for identifying unk

40 ess, since pretreatment with the soluble Fas immunoadhesin reduces liver injury in this model.

41 activation of EphA by infusion of an agonist immunoadhesin results in enhanced performance on these t

42 For the antibodies VRC01, PG9, and PG16, the immunoadhesins showed modestly reduced potencies, likely

43 Immunoadhesin (single-chain fragment variable [scFv]-Fc)

44 The immunoadhesin specifically bound to adult T cells, B cel

45 Initial studies using immunoadhesins suggest that protein targeting might be a

46 for EphA receptors, we designed recombinant immunoadhesins that specifically bind to the receptor bi

47 a novel tumor necrosis factor-alpha receptor immunoadhesin, the increased mortality was completely pr

48 Thirty-five point mutants of the ICAM-1 immunoadhesin were generated and residues important for

49 These immunoadhesins were secreted to the cell culture medium

50 The recombinant SU-immunoadhesins were used as probes to investigate the ce

51 dentified in a screen for binding to MuSK-Fc immunoadhesin, were examined for ability to induce proli